Patent Expiry

Patent/Exclusivity Expiry: VANFLYTA

Other upcoming events for KURA

Phase 3 ReadoutPhase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit
Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ
Patent ExpiryPatent/Exclusivity Expiry: CABOMETYX
Patent ExpiryPatent/Exclusivity Expiry: XOSPATA
Patent ExpiryPatent/Exclusivity Expiry: IMKELDI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: VANFLYTA — KURA Patent Expiry | BioSniper